×

img Accessibility Controls

Technologies Banner

All Technologies

A study for safety and efficacy of VELGRAFT containing Human Bone marrow derived Mesenchymal Stem Cell and Mesenchymal stem cell differentiated adipocytes as a skin substitute on wounds of Diabetic Foot Ulcers

Implementing Organization

Project Overview

Velgraft is a biocompatible and biodegradable skin substitute, and all the constituents of Velgraft has been in medical use for many years and their trouble free records serves to underline the safety of this product. Mesenchymal stem cell has been used widely used for the treatment of many diseases and they have been proved to be non-immunogenic and non-tumorigenic. Additionally, cells contained in Velgraft are cultured in xenogeneic free medium, reducing risk of sensitivity to animal products. The flexible and porous matrix of Velgraft is comprised of natural polymers which help in reducing the healing time.

Benefits

1. Indigenously developed and manufactured

2. Once developed will be Availability in the local market.

3. VELGRAFT is immunologically inert- ensuring well-tolerance and less rejection from the graft recipient.

4. Optimized cold transport system with real time monitoring and delivering in short duration.

5. Increased accessibility, and reduced turnaround time & cost.
Funding Organization
Quick Information
Thrust Areas
Medical Sciences
Focus Area
Devices and Diagnostics, Wound healing implant, Biopharma
Status
Pre-commercilization stage (Phase-I clinical trials are completed and CDSCO application is under process, Phase-II trials will be initiated after CDSCO approval)
Output
Status
Pre-commercilization stage (Phase-I clinical trials are completed and CDSCO application is under process, Phase-II trials will be initiated after CDSCO approval)
TRL: Technology Readiness Level
TRL 7
arrowtop
Latest Updates
Loading…